Canada's Natural Health Products (NHP) sector is facing a persistent challenge: the gap between policy intent and operational reality. Despite the federal government's stated priority of reducing red tape, recent updates indicate that meaningful burden reduction depends on how reforms to licensing, labeling, and system operations are implemented. While the government has signaled positive intentions through sector-specific changes, such as potential reforms to product licensing pathways and labeling requirements, early indications suggest these measures may only provide modest relief if not designed as proper modernization efforts. The industry is closely monitoring these discussions to ensure real flexibility and avoid incremental adjustments that add new elements without clear benefits. The sector continues to experience 'hidden red tape', a burden driven not by regulation itself but by its implementation by Health Canada. Companies report inconsistent interpretation of requirements, evolving and sometimes expanding evidence expectations, and a lack of predictability in the review process. Even when guidance documents and monographs exist, submissions are frequently subject to additional information requests, creating delays and increasing costs. Recent updates to Good Manufacturing Practices (GMP) further illustrate this trend, increasing documentation and compliance burdens, disproportionately affecting small and medium-sized enterprises (SMEs) due to significant cost increases in a short time period. Competitiveness pressures are intensifying, with concerns about the uneven enforcement landscape, particularly in cross-border e-commerce. Canada's '90-day personal importation' provision is being used at a commercial scale, allowing foreign products to enter the market without meeting the same regulatory requirements as domestic products, creating an uneven playing field and undermining compliant Canadian businesses. This raises broader questions about regulatory sovereignty and consumer protection. To address these dynamics, the industry is calling for targeted and outcomes-focused red tape reduction. They demand licensing reforms that deliver meaningful reductions in both time and cost, a true modernization of labeling that prioritizes flexibility, greater consistency and transparency in evidence requirements and regulatory decision-making, operational improvements within Health Canada, and modernized enforcement approaches that address cross-border disparities and restore competitive balance. Canada has an opportunity to reestablish itself as a global leader in the NHP sector. However, this will require moving beyond high-level commitments and ensuring that current reform initiatives translate into measurable, on-the-ground reductions in industry's burden.
